Gene Therapy in Cardiology represents a revolutionary frontier in cardiovascular medicine, aiming to correct genetic defects, modulate molecular pathways, and enhance cardiac repair. This session explores current scientific understanding, clinical trial progress, vector platforms, delivery challenges, and future therapeutic opportunities. With rising global interest, researchers increasingly search for a dedicated cardiology conference to understand this rapidly expanding field.

The description reviews the molecular basis of cardiovascular disease, focusing on inherited cardiomyopathies, arrhythmia syndromes, hypertension-related changes, vascular dysfunction, and heart failure. Participants will understand how genetic variants and molecular signaling drive disease progression, and how gene therapy aims to modify these pathways.

A major component is implementing advanced cardiology gene therapy strategies, exploring gene replacement, gene silencing (RNAi), genome editing (CRISPR/Cas9), AAV-based vectors, lipid nanoparticles, viral vs. non-viral delivery, and tissue-targeted distribution. The session covers cardiac-specific promoters, vector tropism, off-target risks, and immune responses that influence therapy success.

Case discussions explore applications in Duchenne cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic syndromes, lipid disorders, ischemic tissue repair, and congenital heart defects. Participants will review preclinical breakthroughs and early-phase clinical trial outcomes.

Future innovations include base editing, prime editing, programmable epigenetic modification, multi-vector systems, mRNA therapies, and precision delivery through catheter-based platforms. By the end of this session, attendees will appreciate how gene therapy is shaping the next generation of cardiovascular care.